CGF1
MCID: CGN007
MIFTS: 27

Cognitive Function 1, Social (CGF1)

Aliases & Classifications for Cognitive Function 1, Social

MalaCards integrated aliases for Cognitive Function 1, Social:

Name: Cognitive Function 1, Social 57 70
Cognitive Function-1, Social 13
Social Cognition 57
Cgf1 57

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
x-linked imprinting


External Ids:

OMIM® 57 300082
MedGen 41 C1848140
SNOMED-CT via HPO 68 88425004
UMLS 70 C1848140

Summaries for Cognitive Function 1, Social

MalaCards based summary : Cognitive Function 1, Social, also known as cognitive function-1, social, is related to schizophrenia and autism spectrum disorder. An important gene associated with Cognitive Function 1, Social is CGF1 (Cognitive Function 1, Social). The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and spinal cord, and related phenotype is abnormality of the nervous system.

More information from OMIM: 300082

Related Diseases for Cognitive Function 1, Social

Diseases related to Cognitive Function 1, Social via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 schizophrenia 11.0
2 autism spectrum disorder 10.9
3 autism 10.8
4 major affective disorder 8 10.7
5 major affective disorder 9 10.7
6 bipolar disorder 10.7
7 frontotemporal dementia 10.7
8 multiple sclerosis 10.6
9 psychotic disorder 10.6
10 dementia 10.6
11 brain injury 10.6
12 traumatic brain injury 10.6
13 personality disorder 10.5
14 borderline personality disorder 10.5
15 epilepsy 10.5
16 schizoaffective disorder 10.5
17 alexithymia 10.5
18 attention deficit-hyperactivity disorder 10.4
19 depression 10.4
20 agenesis of corpus callosum, cardiac, ocular, and genital syndrome 10.4
21 mental depression 10.4
22 major depressive disorder 10.4
23 post-traumatic stress disorder 10.4
24 digeorge syndrome 10.4
25 alzheimer disease 10.4
26 asperger syndrome 10.4
27 relapsing-remitting multiple sclerosis 10.4
28 anorexia nervosa 10.3
29 anxiety 10.3
30 eating disorder 10.3
31 williams-beuren syndrome 10.3
32 amyotrophic lateral sclerosis 1 10.3
33 mild cognitive impairment 10.3
34 lateral sclerosis 10.3
35 mood disorder 10.3
36 temporal lobe epilepsy 10.3
37 aphasia 10.3
38 alcohol use disorder 10.3
39 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 10.2
40 alacrima, achalasia, and mental retardation syndrome 10.2
41 social phobia 10.2
42 huntington disease 10.2
43 parkinson disease, late-onset 10.2
44 fragile x syndrome 10.2
45 ataxia and polyneuropathy, adult-onset 10.2
46 alcohol dependence 10.2
47 dysphasia, familial developmental 10.2
48 specific language impairment 10.2
49 schizotypal personality disorder 10.2
50 amnestic disorder 10.2

Graphical network of the top 20 diseases related to Cognitive Function 1, Social:



Diseases related to Cognitive Function 1, Social

Symptoms & Phenotypes for Cognitive Function 1, Social

Human phenotypes related to Cognitive Function 1, Social:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 31 HP:0000707

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Neuro:
social adjustment
verbal and higher-order executive function skills
development of sexual dimorphism in social behavior

Clinical features from OMIM®:

300082 (Updated 20-May-2021)

Drugs & Therapeutics for Cognitive Function 1, Social

Drugs for Cognitive Function 1, Social (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
3
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
4
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
5
Iloperidone Approved Phase 4 133454-47-4 71360
6 Gastrointestinal Agents Phase 4
7 Antiemetics Phase 4
8 Dopamine Agents Phase 4
9 Dopamine Antagonists Phase 4
10 Psychotropic Drugs Phase 4
11 Antipsychotic Agents Phase 4
12
Nicotine Approved Phase 2, Phase 3 54-11-5 942 89594
13
Bupropion Approved Phase 2, Phase 3 34911-55-2, 34841-39-9 444
14 Neurotransmitter Agents Phase 2, Phase 3
15 Central Nervous System Stimulants Phase 2, Phase 3
16 Dopamine Uptake Inhibitors Phase 2, Phase 3
17 Antidepressive Agents Phase 2, Phase 3
18 Cholinergic Agents Phase 2, Phase 3
19 Nicotinic Agonists Phase 2, Phase 3
20 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
21
Lactitol Approved, Investigational Phase 2 585-86-4 157355
22
Guanfacine Approved, Investigational Phase 2 29110-47-2 3519
23
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
24
Hydroxocobalamin Approved Phase 2 13422-51-0 11953898 15589840
25
Methylcobalamin Approved, Investigational Phase 2 13422-55-4
26
Emtricitabine Approved, Investigational Phase 2 143491-57-0 60877
27
Coal tar Approved Phase 2 8007-45-2
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
29
Cyanocobalamin Approved, Nutraceutical Phase 2 68-19-9 44176380
30
Cobalamin Experimental Phase 2 13408-78-1 6857388
31
Tenofovir Experimental, Investigational Phase 2 147127-20-6 464205
32 Micronutrients Phase 2
33 Trace Elements Phase 2
34 Nutrients Phase 2
35 Hormones Phase 2
36 Vitamins Phase 2
37 Adrenergic Agents Phase 2
38 Anti-Infective Agents Phase 2
39 Adrenergic alpha-Agonists Phase 2
40 Adrenergic Agonists Phase 2
41 Antihypertensive Agents Phase 2
42 Anti-Retroviral Agents Phase 2
43 Antiviral Agents Phase 2
44 Vitamin B Complex Phase 2
45 Folate Phase 2
46 Vitamin B12 Phase 2
47 Vitamin B 12 Phase 2
48 Vitamin B9 Phase 2
49 Hematinics Phase 2
50 Reverse Transcriptase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 300)
# Name Status NCT ID Phase Drugs
1 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
2 The Cognitive Effects of Risperidone and Olanzapine Completed NCT00108368 Phase 4 Risperidone;Olanzapine
3 Physical Exercise and Pollution: Cardiorrespiratory, Cerebral and Molecular Aspects. Completed NCT02304731 Phase 4
4 The Effects of Intranasal Oxytocin on Social Cognition, Implicit Preferences and Craving in Moderate to Heavy Social Alcohol Drinkers Completed NCT01829516 Phase 4 Oxytocin;Placebo
5 Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers (PELICAN) Completed NCT02098369 Phase 4
6 Effects of Oxytocin on Social Cognition Training: Relationship to Target Engagement Recruiting NCT03245437 Phase 4 Oxytocin nasal spray;Placebo nasal spray
7 An Exploratory Study to Assess the Effects of Fanapt® on Social Cognitive Performance Terminated NCT01929889 Phase 4 Iloperidone
8 Educational Intervention on Weight Management in Chinese American Children Completed NCT00522964 Phase 3
9 Combined Smoking Cessation and Cognitive Processing Therapy for PTSD Completed NCT01901848 Phase 2, Phase 3 Bupropion;nicotine replacement therapy (NRT)
10 The Positively Quit Trial: Addressing Disproportionate Smoking Rates Among People Living With HIV Recruiting NCT04449458 Phase 3
11 Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors Recruiting NCT03781154 Phase 3
12 Effects of Oxytocin on Emotion Recognition and Response Inhibition Unknown status NCT02350946 Phase 2 Oxytocin;Placebo
13 A Randomized, Placebo Controlled, Double-blind, 3-period Cross-over Study in Adult Patients With Autism Spectrum Disorders Evaluating Cognitive Response After Single- Dose Oxytocin 8 or 24 IU Intranasal Administration Using the OptiNose Bi-directional Nose-to-brain Device Completed NCT02414503 Phase 1, Phase 2 8IU intranasal oxytocin;24IU intranasal oxytocin;Placebo
14 Epidemiologic Study on Changing HIV Risks Among FSW-IDUs on the Mexico-US Border Completed NCT00840658 Phase 2
15 Oxytocin and Social Cognition in Schizophrenia Completed NCT00884897 Phase 2 Oxytocin;Placebo
16 Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail Completed NCT00618280 Phase 1, Phase 2 nicotine nasal spray
17 Effect of Intranasal Oxytocin on Social Cognition Completed NCT02671266 Phase 2 Oxytocin;Placebo
18 Oxytocin as Adjunctive Treatment of Schizophrenia Completed NCT01568528 Phase 2 Oxytocin;Placebo
19 Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum Completed NCT02524899 Phase 2 Guanfacine;Placebo
20 Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia Completed NCT01292577 Phase 1, Phase 2
21 Efficacy and Safety of a Hospital Walking Program for Older Adults Completed NCT00715962 Phase 2
22 Enhancing HIV Risk Reduction Among Indian Women With Risky Husbands Completed NCT01592994 Phase 2
23 Does Resilience to Childhood Adversity Improve With Social Intelligence Training Completed NCT03824353 Phase 2
24 Beyond Ageing Project: A RCT to Assess the Benefit of Improving Mental Health Literacy as Well as the Effect of Folate and B12, and Physical Activity, in Preventing Major Depression and Cognitive Decline Among Older Australians Completed NCT00214682 Phase 2 Folate (400mcg) and Vitamin B12 (100 mcg);placebo
25 Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among Young Men Who Have Sex With Men (YMSM) in the United States Completed NCT01772823 Phase 2 Emtricitabine/tenofovir (FTC/TDF (Truvada®))
26 Integrated Oxytocin and Nonverbal, Emotion Recognition, and Theory of Mind Training for Children With Autism Spectrum Disorder Recruiting NCT02918864 Phase 2 Oxytocin and social cognitive skills group
27 Social Intelligence Training for Custodial Grandmothers and Their Adolescent Grandchildren Recruiting NCT03239977 Phase 2
28 Cognitive Remediation of the Ability to Infer Intention of Others in Schizophrenic Patients - A Controlled, Randomized Trial (Phase IIb) Terminated NCT01077791 Phase 2
29 CSP #560 - Bronchitis and Emphysema Advice and Training to Reduce Hospitalization (BREATH) Terminated NCT00395083 Phase 2
30 Social Cognitive Training for Psychosis: Phase I Treatment Development Completed NCT01579422 Phase 1
31 Double-blind, Placebo-controlled, Randomized Study: Oxytocin and OXTR-genotypes Influence Behavioral and Neural Social Reactions Completed NCT01606462 Phase 1 Oxytocin
32 Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia Completed NCT01394471 Phase 1 Intranasal Oxytocin Spray
33 Intranasal (Optinose Bidirectional Nose-to-brain Device) Versus Intravenous Slow Infusion of Oxytocin - a Randomized, Placebo- Controlled Double-blind, Double-dummy 4-period Cross-over Study in Healthy Adult Volunteers Evaluating Brain Functional Magnetic Resonance Imaging Changes, Cognitive Response, Heart Rate Variability, Plasma Pharmacokinetics and Saliva Concentration After Single-dose Oxytocin 8 or 24 International Units (IU) Intranasally or 1 IU as Slow Intravenous Infusion Completed NCT01983514 Phase 1 8IU intranasal oxytocin;24 IU intranasal oxytocin;1 IU intravenous oxytocin;Placebo
34 Pharmacological Approach to Improve the Outcome of Social Cognition Training Completed NCT01517360 Phase 1 Oxytocin
35 Social Cognition and Interaction Training for Schizophrenia Completed NCT00601224 Phase 1
36 Trial of 2 TeleComputer Diet Change Maintenance Programs Completed NCT00148525 Phase 1
37 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Suspended NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
38 Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making Unknown status NCT02526914 Intranasal Oxytocin;Intranasal vasopressin;Intranasal placebo
39 Effects of Intranasal Oxytocin and Vasopressin on Social Behavior in Healthy Controls Unknown status NCT01296269 Oxytocin;Arginine Vasopressin;placebo
40 Oxytocinergic Modulation of Perceived Social Exclusion Unknown status NCT03122067 oxytocin treatment;placebo treatment
41 Rationale, Design and Methods of a Study on Physical Activity, Sedentarism, Physical Fitness, and Brain , Cognitive Performance and Academic Achievement in School Children. The Cogni-Action Project Unknown status NCT03894241
42 Comparison of the Effectiveness of Different Home Exercise Programs in Healthy Individuals Unknown status NCT03878394
43 Cognitive Remediation Plus Aerobic Exercise in Schizophrenia Treatment: a Randomized Controlled Study. Unknown status NCT02864576
44 Treating Social Cognition Impairments in Patients With Schizophrenia With Repetitive Transcranial Magnetic Stimulation (Theta-Burst; TBS); a Pilot Study Unknown status NCT02440867
45 Enhancing Quality Interventions Promoting Healthy Sexuality Unknown status NCT01818791
46 Functional Imaging of Social Cognition in Premanifest Huntington's Disease Unknown status NCT02551705
47 Neural Mechanism Underlying Social Cognition in Depressive Patients Unknown status NCT03413670
48 The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders Unknown status NCT01183221 Syntocinon
49 Exploration of Neural Bases in Social Cognition Unknown status NCT02110017
50 Assessing Changes in Social Cognition and Personality in Patients With Frontotemporal Lobar Degeneration, Alzheimer's Disease and Parkinson's Disease and Their Effect on the Patient-caregiver Relationship Unknown status NCT02964611

Search NIH Clinical Center for Cognitive Function 1, Social

Genetic Tests for Cognitive Function 1, Social

Anatomical Context for Cognitive Function 1, Social

MalaCards organs/tissues related to Cognitive Function 1, Social:

40
Brain, Eye, Spinal Cord, Heart, Temporal Lobe, Pituitary

Publications for Cognitive Function 1, Social

Articles related to Cognitive Function 1, Social:

(show all 13)
# Title Authors PMID Year
1
Xlr3b is a new imprinted candidate for X-linked parent-of-origin effects on cognitive function in mice. 57
15908950 2005
2
Identification of a cluster of X-linked imprinted genes in mice. 57
15908953 2005
3
Turner's syndrome. 57
11498234 2001
4
Retarded postimplantation development of X0 mouse embryos: impact of the parental origin of the monosomic X chromosome. 57
9733570 1998
5
Parental origin-dependent, male offspring-specific transmission-ratio distortion at loci on the human X chromosome. 57
9585588 1998
6
Evidence from Turner's syndrome of an imprinted X-linked locus affecting cognitive function. 57
9192895 1997
7
The Drosophila developmental gene fat facets has a human homologue in Xp11.4 which escapes X-inactivation and has related sequences on Yq11.2. 57
8922996 1996
8
Three genes that escape X chromosome inactivation are clustered within a 6 Mb YAC contig and STS map in Xp11.21-p11.22. 57
7633424 1995
9
Escape from X inactivation in human and mouse. 57
7900190 1995
10
A paternally imprinted X chromosome retards the development of the early mouse embryo. 57
8375333 1993
11
Arabidopsis Chloroplast protein for Growth and Fertility1 (CGF1) and CGF2 are essential for chloroplast development and female gametogenesis. 61
32306898 2020
12
Genes regulating gland development in the cotton plant. 61
30467959 2019
13
Performance and digestion by steers grazing tall fescue and supplemented with energy and protein. 61
9655590 1998

Variations for Cognitive Function 1, Social

Expression for Cognitive Function 1, Social

Search GEO for disease gene expression data for Cognitive Function 1, Social.

Pathways for Cognitive Function 1, Social

GO Terms for Cognitive Function 1, Social

Sources for Cognitive Function 1, Social

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....